No	REC Reference Number	IRAS No	Title	Date of First Patient Recruitment	Benchmark Met	Date site invited	Date site selected	HRA Approval date	Date site confirmed by sponsor	Date site confirmed	Date site ready to start	A - Permissions delayed/ denied	B - Suspended by Sponsor	C - Closed by Sponsor	D - Sponsor delays	E - Staff Availability issues	F - No Eligible Patients (No patient seen)	G - No Patients Consented	H - Contracting Delays	I-Rare disease	J-Other	Comments	Source of delay
1	17/NS/0018	223787	Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study); a superiority randomised clinical trial to evaluate the effectiveness and cost effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms		N/A	07/09/2017	17/11/2017	11/08/2017	17/11/2017	17/11/2017	13/12/2017											N/A as 70 day benchmark not exceeded at time of report period	
2	16/LO/1099	181655	A randomized phase III trial comparing conventional-dose chemotherapy using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with high-dose chemotherapy using mobilizing Paclitaxel plus Ifosfamide followed by high-dose carboplatin an Etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors (TIGER)		N/A	12/10/2016	11/12/2017	11/12/2017	21/12/2017	21/12/2017											N/A as 70 day benchmark not exceeded at time of report period	
3	17/YH/0249	225721	Optimising Behavioural Observation Audiometry (BOA) in Adults with Learning Disabilities		N/A	05/07/2017	14/11/2017	14/11/2017	16/11/2017	16/11/2017	16/11/2017											N/A as 70 day benchmark not exceeded at time of report period	
4	17/LO/1147	222154	A Randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab monotherapy in subjects with moderate-to-severe atopic dermatitis who are candidates for systemic therapy		N/A	27/03/2017	09/11/2017	10/08/2017	15/11/2017	21/11/2017	29/12/2017											N/A as 70 day benchmark not exceeded at time of report period	
5	17/EE/0297	225586	A Single-Arm, Multicentre Phase IIIB Clinical Trial to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients with Inhibitors		N/A	10/08/2017	07/11/2017	06/09/2017	19/12/2017	21/12/2017												N/A as 70 day benchmark not exceeded at time of report period	
6	17/NE/0027	215796	CReST 2 - Colorectal Endoscopic Stenting Trial 2		N/A	05/07/2017	09/11/2017	03/04/2017	30/08/2017	17/11/2017												N/A as 70 day benchmark not exceeded at time of report period	
7	17/LO/1018	224051	AstraZeneca, D4191C00068, An Open-Label, Multi-Centre, Safety Study of Fixed Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies (STRONG) – Core Protocol, 233675		N/A	21/06/2017	07/12/2017	13/09/2017	13/12/2017	15/12/2017												N/A as 70 day benchmark not exceeded at time of report period	
8	17/WS/0120	225090	A multi-center, double-blind, placebo-controlled, Phase 4 study in patients with pulmonary arterial hypertension to assess the effect of selexipag on daily life physical activity and patient's self-reported symptoms and their impacts		N/A	05/10/2017	06/12/2017	24/07/2017	12/12/2017	15/12/2017	22/12/2017											N/A as 70 day benchmark not exceeded at time of report period	
9	16/SS/0070	202282	PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke. A randomised, open, phase III, clinical trial with blinded outcome assessment.		N/A	09/06/2017	10/11/2017	05/06/2017	01/12/2017	05/12/2017												N/A as 70 day benchmark not exceeded at time of report period	
10	16/EM/0436	213166	Single arm study of ALXN1210 in complement inhibitor treatment-naïve adult and adolescent patients with Atypical Hemolytic Uremic Syndrome (aHUS)		N/A	11/07/2017	01/11/2017	07/12/2016	27/10/2017	03/11/2017												N/A as 70 day benchmark not exceeded at time of report period	

11	17/EM/0005	215706	A double-blind, randomised, placebo-controlled, multicentre study to assess the efficacy and safety of on mortality and morbidity in subject with chronic heart failure with reduced ejection fraction (GALACTIC-HF)		N/A	10/08/2017	07/11/2017	15/02/2017	30/10/2017	08/11/2017	29/11/2017											N/A as 70 day benchmark not exceeded at time of report period	
12	16/LO/1004	207544	Modulation of immune response and outcomes in ALS using IL-2 (MIROCALS-IL2)	11/07/2017	No	09/09/2016	16/03/2017	06/10/2016	21/03/2017	04/04/2017	10/07/2017				Y							Sponsor delayed confirmation of study open to recruitment at site	Sponsor
13	16/EE/0370	198596	MesoTRAP: A feasibility study comparing video-assisted thoracoscopic partial pleurectomy/decortication with indwelling pleural catheter in patients with trapped lung and pleural effusion due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial.		No	16/12/2016	05/05/2017	11/01/2017	05/05/2017	09/05/2017	15/09/2017				Y							Sponsor delayed confirmation of study open to recruitment at site	Sponsor
14	17/LO/0718	213056	PREvention of Cerebral Ischaemia in Stent treatment for carotid artery stenosis - A randomised trial of optimised antiplatelet therapy with outcome assessment on MRI (PRECISE-MRI)		No	11/04/2017	09/08/2017	24/07/2017	10/10/2017	20/10/2017					Y				Y			Contracting delays with Sponsor, and Sponsor delay in provision of equipment	Sponsor
15	16/EE/0234	194284	Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study.		No	15/06/2016	25/05/2017	12/09/2016	25/05/2017	25/05/2017	19/07/2017				Y			Y				Sponsor delay in site initiation. Eligible patients seen chose not to participate in study.	Sponsor
16	17/LO/1236	225042	Determining the predictive utility of short-term variation (STV) of fetal heart rate (FHR) for fetal acidaemia, and the feasibility of using this for decision making in high-risk women during labour		No	29/06/2017	22/08/2017	22/08/2017	19/12/2017	19/12/2017	19/12/2017								Y			Contracting delays with device manufacturer	Neither
17	17/YH/0179	226816	Developing and Testing a Clinical Grade Magnetic Impedance Spectroscopy Device for Cervical Assessment to Predict Preterm Birth		No	11/05/2017	05/09/2017	20/09/2017	18/10/2017	18/10/2017	18/10/2017	Y			Y							Relevent permissions delayed and not granted in time. Planned and agreed later start.	Neither
18	16/LO/1386	199366	Phase 2 Study: A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Cardiac and Renal Effects of 7 Day Treatment with 'Elamipretide' in Patients Hospitalized with Severe Congestion due to Heart Failure.		No	07/06/2016	09/02/2017	14/11/2016	15/02/2017	20/02/2017	10/03/2017				Y			Y				Sponsor delayed confirmation of study open to recruitment at site and eligible patients chose not to participate in the study due to intensity	Neither
19	17/NW/0236	196147	Support, Positioning and Organ Stabilisation during Breast Cancer Radiation Therapy: The SuPPORT 4 All bra.	30/10/2017	No	03/05/2017	11/07/2017	18/05/2017	26/07/2017	03/08/2017	10/10/2017				Y				Y			Sponosor delayed confirmation of study open to recruitment at site	Sponsor
20	17/NE/0135	157987	A Study Investigating Whether Vitamin and Mineral Supplementation Enhances Cognitive Outcome in Mild to Moderate Brain Injury, Compared to a Control Group		No	10/05/2017	17/07/2017	17/07/2017	07/08/2017	07/08/2017	18/09/2017				Y							Sponsor delay in provision of placebo and delayed confirmation of study open to recruitment at site	Sponsor
21	16/EM/0376	211430	A 12-week, randomized, multi-center, double-blind, placebo-controlled, 3-arm, parallel-group, phase 3 trial to evaluate the efficacy and safety of 2 doses of AQX-1125 targeting the SHIP1 pathway in subjects with interstitial cystitits/bladder pain syndrome followed by a 2-arm, 14 or 40 week open label extension	09/05/2017	No	12/10/2016	12/01/2017	07/12/2016	07/02/2017	10/02/2017	10/02/2017						Y					Patients screened but no eligible patients identified until after 70 days had passed	Neither

22	16/NW/0620	206738	Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating The Efficacy And Safety Of Oral Vadadustat For The Correction Of Anemia In Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT – CORRECTION)	10/08/2017	No	13/10/2016	08/03/2017	17/11/2016	08/03/2017	20/03/2017	17/05/2017				Y							Sponsor delayed confirmation of study open to recruitment at site until after 70 days had passed	Sponsor
23	16/SC/0439	199315	ACL Surgery Necessity in Non Acute Patients Comparison of the clinical and cost effectiveness of two management strategies for non-acute Anterior Ligament (ACL) injury: Rehabilitation versus surgical Reconstruction	12/07/2017	No	23/02/2017	15/03/2017	16/11/2016	15/03/2017	10/04/2017	05/06/2017						Y					Patients screened but no eligible patients identified	Neither
24	16/WS/0165	190574	ADSCaN: A randomised Phase II study of accelerated, dose escalated, sequential chemo-radiotherapy in non-small cell lung cancer	16/10/2017	No	15/03/2017	29/05/2017	13/02/2017	09/08/2017	16/08/2017	22/08/2017						Y		Y			Contracting delays with Sponsor	Sponsor
25	16/EM/0384	182787	CV 185316: An Open-label, 2x2 Fractorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrilation and Acute Coronary Syndrome or Percutaneous Coronary Intervention	27/06/2017	No	25/08/2016	31/01/2017	21/11/2016	30/01/2017	01/02/2017	03/02/2017						Y					Strict patient eligibility criteria	Neither
26	17/YH/0083	220358	A randomised controlled trial of routine massage with a new lotion for the enhancement of skin health and cognitive development in infants		No	01/02/2017	08/06/2017	08/06/2017	15/06/2017	19/06/2017					Y							Planned and agreed later start date due to intrinsic study design	Sponsor
27	16/EE/0356	207367	A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn's Disease.		No	27/10/2016	27/02/2017	21/11/2016	28/02/2017	09/03/2017	18/05/2017				Y		Y					Sponsor delayed confirmation of study open to recruitment at site. Patients screened but very few eligible patients identified.	Sponsor
28	17/NW/0180	220257	A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy		No	06/10/2016	26/07/2017	04/04/2017	26/07/2017	03/08/2017	22/09/2017						Y			Y		Rare disease, patients screened but no eligible patients identified	Neither
29	16/SC/0653	215441	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy		No	22/12/2016	17/10/2017	21/03/2017	24/10/2017	30/10/2017	11/12/2017				Y							Sponsor delayed site intitiation visit.	Sponsor
30	16/SC/0271	187103	The UK plasma based molecular profiling of advanced breast cancer to inform therapeutic choices (plasmaMATCH) Trial: A multiple parallel cohort, open-label, multicentre Phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening		No	17/10/2016	19/06/2017	21/09/2016	23/10/2017	10/11/2017	23/11/2017							Y	Y			Contracting delays with NHS Provider	NHS Provider

31	17/LO/0440	217506	Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 814907 in Patients with Mild Alzheimer's Disease		No	24/11/2016	27/07/2017	27/07/2017	27/07/2017	03/08/2017	22/08/2017							Y				Eligible patients seen chose not to participate in the study.	Neither
32	17/LO/1170	219279	SERENADE: A multi-center, double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular disease		No	04/05/2017	09/10/2017	02/08/2017	19/10/2017	02/11/2017	13/12/2017				Y							Sponsor delayed confirmation of study open to recruitment at site.	Sponsor
33	17/SC/0231	221097	ETOP 9-15 PROMISE-meso - A multicentre randomised Phase III trial comparing Pembolizumab versus standardchemotherapy for advanced pre-treated malignant pleural mesothelioma	26/10/2017	No	25/11/2016	12/07/2017	27/06/2017	14/07/2017	26/09/2017	25/10/2017				Y				Y			Contracting delays with Sponsor	Sponsor
34	16/NS/0094	206213	Bioimpedance Spectroscopy To Maintain Renal Output: The BISTRO Trial		No	05/05/2017	04/08/2017	04/10/2016	11/08/2017	11/08/2017	06/09/2017					Y		Y				NHS Provider staff availability	NHS Provider
35	17/EM/0155	206803	Multicenter, randomized, double-blind, parallel-group, add-on, superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera®) - POINT	31/10/2017	No	05/05/2017	11/07/2017	10/07/2017	17/07/2017	27/07/2017					Y							Sponsor delayed confirmation of study open to recruitment at site.	Sponsor
36	17/LO/0243	219613	A randomized, double-blind, multi-dose, placebo-controlled study to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus in patients with primary biliary cholangitis. (GLIMMER: GSK2330672 triaL of Ibat inhibition with Multidose Measurement for Evaluation of	04/09/2017	No	09/03/2017	12/05/2017	27/03/2017	12/05/2017	23/05/2017	04/08/2017					Y						NHS provider staff availability	NHS Provider
37	17/LO/0380	218003	A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of Crenezumab in patients with prodromal to mild Alzheimer's disease - Cread 2		No	05/01/2017	29/06/2017	18/05/2017	29/06/2017	29/06/2017	31/07/2017				Y		Y					Sponsor delayed confirmation of study open to recruitment at site.	Sponsor
38	17/SC/0023	220276	A Phase 2 study to investigate the efficacy, safety, and tolerability of six weeks treatment with V565 in subjects with active Crohn's disease		No	10/01/2017	03/04/2017	08/02/2017	04/04/2017	10/04/2017	23/05/2017				Y		Y					Sponsor delayed confirmation of study open to recruitment at site. Patients screened but no eligible patients identified.	Sponsor
39	16/EM/0181	201126	TAMARIN: Effects of TAMoxifen on the Mutant Allele Burden and Disease Course in Patients with MyeloprolifeRaTive Neoplasms		No	25/01/2017	16/06/2017	02/06/2016	04/05/2017	28/09/2017	28/09/2017					Y	Y					NHS Provider staff availability	NHS Provider
40	17/EE/0205	224373	A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma		No	25/04/2017	05/10/2017	25/07/2017	06/10/2017	17/10/2017	03/11/2017						Y			Y		Patients screened but no eligible patients identified. Also rare disease	Neither
41	17/LO/0046	220052	Evaluation of safety following Immune Tolerance Induction treatment with turoctocog alfa in patients with haemophilia A following inhibitor development in NN7170-4213 trial		No	10/02/2017	10/02/2017	15/02/2017	18/04/2017	20/04/2017	20/04/2017				Y		Y					Main source of delay was Sponsor delay in study set up as site was to be a later additional site. Patients screened but no eligible patients identified.	Sponsor

42	17/LO/0525	221541	A prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 6-month study assessing the safety and ocular hypotensive efficacy of PG324 Ophthalmic Solution compared to GANFORT® (bimatoprost 0.03% / timolol 0.5% Opthalmic Solution) in subjects with elevated intraocular pressure (MERCURY 3)	17/10/2017	No	06/02/2017	04/07/2017	30/06/2017	01/06/2017	06/07/2017	17/07/2017				Y							Sponsor delayed confirmation of study open to recruitment at site	Sponsor
43	17/NW/0162	220300	HER2CLIMB – Phase 2 randomised, double-blinded, controlled study of Tucatinib vs placebo in combination with Capecitabine and Trastuzumab in patients with pretreated unresectable locally advanced or metastatic HER2+ breast cancer		No	02/02/2017	10/10/2017	11/05/2017	11/10/2017	13/10/2017	19/10/2017						Y					No patients seen, strict patient eligibility criteria.	Neither
44	16/EM/0443	208418	STEM – A multicentre Phase 2 study of SFX-01 treatment and evaluation in patients with Estrogen Receptor (ER) positive and Human Epidermal Growth Factor Receptor 2 (HER2) negative metastatic breast cancer progressing on either an Aromatase Inhibitor (AI) or Tamoxifen or Fulvestrant		No	06/02/2017	17/07/2017	15/12/2016	01/08/2017	04/08/2017	25/08/2017						Y					No eligible patients seen, strict patient eligibility criteria.	Neither
45	17/LO/0041	219676	CardioMEMS Heart Failure System "Outside US" Post-Approval Study		No	04/04/2017	04/07/2017	06/03/2017	29/06/2017	13/07/2017	26/07/2017						Y					Patients screened but no eligible patients identified.	Neither
46	16/EM/0344	180454	The Effect of MultiPoint Pacing on reverse remodelling and the incidence of ventricular arrhythmias – The MPP-VARR Study	12/12/2017	No	16/06/2017	31/08/2017	26/10/2016	05/09/2017	05/09/2017	07/09/2017						Y					Patients screened but no eligible patients identified	Neither
47	16/EM/0172	194491	Non-vitamin K antagonist oral anticoagulants in patients with atrial high rate episodes (NOAH - AFNET 6)	24/10/2017	No	28/03/2017	13/07/2017	24/05/2016	26/06/2017	13/07/2017	20/07/2017						Y					Patients screened but no eligibile patients identified.	Neither
48	16/WS/0223	213242	A prospective, randomized, international, multicenter, double-arm, controlled, open-label study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phosphodiesterase-5 inhibitors (PDE-5i) with or without endothelin receptor antagonist (ERA), but not at treatment goal		No	13/04/2017	18/07/2017	31/01/2017	20/07/2017	27/07/2017	27/07/2017				Y		Y			Y		Sponsor delayed confirmation of study open to recruitment at site. Patients screened but no eligible patients identified	Sponsor
49	17/WS/0072	221444	Edoxaban versus standard of care and their effects on clincal outcomes in patients having undergone transcatheter aortic valve implantation – in atrial fibrillation (ENVISAGE)		No	09/05/2017	14/07/2017	06/06/2017	20/07/2017	27/07/2017	27/09/2017				Y							Sponsor delayed confirmation of study open to recruitment at site. Sponsor delay in provision of IMP	Sponsor
50	16/WM/0451	197521	Pilot Study for a randomised trial comparing the influence of forced air versus resistive fabric warming technologies on post-operative infection rates following orthopaedic implant surgery in adults [RIIiO]		No	13/09/2017	04/10/2017	07/11/2016	05/10/2017	06/10/2017	07/12/2017					Y						NHS Provider staff availability	NHS Provider
51	16/SC/0651	213404	An evaluation of the tolerance, compliance and acceptability of a ready to use, liquid, high energy, high protein, peptide-based feed for adults in need of nutrition support – a pilot study		No	14/07/2017	26/07/2017	13/01/2017	27/07/2017	03/08/2017	21/08/2017		Y									Study suspended by sponsor at all sites	Sponsor
52	16/LO/1992	216381	Beyond education: A Hypoglycaemia Awareness Restoration Programme for people with type 1 diabetes and problematic hypoglycaemia persisting despite optimised self-care (HARPdoc)	18/07/2017	Yes	18/01/2017	09/05/2017	10/01/2017	16/05/2017	22/05/2017	25/05/2017												

53	16/YH/0459	213518	Optimal Pathway for TreatIng neurOpathic paiN in Diabetes Mellitus (OPTION-DM) trial	31/10/2017	Yes	07/10/2016	19/09/2017	24/07/2017	26/09/2017	26/09/2017	02/10/2017												
54	16/NW/053	195854	Efficacy and safety of a Double Icodextrin Dose in elderly incident CAPD patients on Incremental peritoneal dialysis therapy : The DIDo Study	15/11/2017	Yes	22/06/2017	08/09/2017	02/11/2016	31/08/2017	08/09/2017	18/10/2017												
55	16/WS/0154	205571	Occupational Therapy Environmental assessment and falls [OTIS]	02/02/2017	Yes	15/09/2016	09/01/2017	08/09/2016	31/01/2017	31/01/2017	31/01/2017												
56	17/YH/0213	210535	A split mouth randomised controlled clinical trial of photodynamic therapy (PDT) as adjunctive therapy to root surface debridement (RSD), compared to RSD alone in the treatment of residual periodontal pockets in	25/10/2017	Yes	19/05/2017	13/10/2017	14/09/2017	13/10/2017	13/10/2017	13/10/2017												
57	17/LO/0326	221071	Using Virtual Reality as a distraction technique to reduce pain during burn treatments.	04/07/2017	Yes	07/02/2017	03/05/2017	24/03/2017	03/05/2017	04/05/2017	15/05/2017												
58	16/EM/0320	208246	A Randomized, Multicentre, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in combination with Atezolizumab or Atezolizumab-Placebo in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer who have Received Prior Trastuzumab and Taxane Base Therapy [KATE-2]	13/02/2017	Yes	24/01/2017	24/01/2017	15/11/2016	26/01/2017	07/02/2017	10/02/2017												
59	16/NW/0517	188554	Accord Myeloma XII: A phase 3 study to determine the role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma.	29/06/2017	Yes	10/05/2016	22/06/2017	27/10/2016	22/06/2017	22/06/2017	27/06/2017												
60	16/LO/1069	200813	PALLAS – PALbociclib CoLlaborative Adjuvant Study: A randomised Phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.	30/06/2017	Yes	18/07/2016	11/05/2017	06/09/2016	20/04/2017	11/05/2017	16/06/2017												
61	17/LO/0402	209419	A Phase III, multicentre, randomised, placebo-controlled, double-blind study of Atezolizumab (anti-PD-L1 antibody) as adjuvant therapy in patients with PD-L1-selected renal cell carcinoma at intermediate to high risk of developing metastasis following nephrectomy. IMMOTION	25/08/2017	Yes	21/01/2017	30/06/2017	09/06/2017	04/07/2017	07/07/2017	26/07/2017												
62	16/YH/0450	213782	20150288: A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL)	21/03/2017	Yes	25/01/2017	25/01/2017	25/01/2017	08/02/2017	13/02/2017	15/02/2017												
63	16/SC/0391	208610	A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis.	12/04/2017	Yes	05/09/2016	24/02/2017	13/10/2016	24/02/2017	06/03/2017	15/03/2017												

64	17/NE/0115	218417	Multi-center, international, double-blind, two-arm, randomized, placebo-controlled phase II trial of pirfenidone in patients with unclassifiable progressive fibrosing ILD	31/07/2017	Yes	07/12/2016	01/06/2017	26/05/2017	14/06/2017	23/06/2017	23/06/2017												
65	17/WM/0216	225761	Investigating the benefits of a 3D camera for recording healing wound dimensions	27/07/2017	Yes	04/05/2017	29/06/2017	30/06/2017	10/07/2017	10/07/2017	10/07/2017												
66	16/EE/0463	214371	COMPLEEMENT-1: An open-label, multicentre, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease	26/04/2017	Yes	19/10/2016	20/02/2017	30/01/2017	22/02/2017	23/02/2017	28/03/2017												
67	16/YH/0506	212039	A Randomized, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of PT009 compared to PT005 on COPD Exacerbations over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD	22/05/2017	Yes	10/01/2017	31/03/2017	22/02/2017	03/04/2017	11/04/2017	04/05/2017												
68	17/NS/0020	224422	Double blind randomised controlled trial of Remote Ischemic preconditioning in Multiple sclerosis	02/05/2017	Yes	28/12/2016	17/03/2017	17/03/2017	05/04/2017	05/04/2017	05/04/2017												
69	17/YH/0103	221203	Prolonged ENoxapariN in primarY Percutaneous Coronary Intervention; a Pilot Pharmacodynamic study (PENNY PCI)	14/06/2017	Yes	13/03/2017	23/05/2017	23/05/2017	12/06/2017	12/06/2017	12/06/2017												
70	16/SC/0484	208568	An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) CheckMate 651	25/07/2017	Yes	04/01/2017	31/05/2017	10/02/2017	01/06/2017	12/06/2017	14/06/2017												
71	16/LO/1794	213087	Safety, tolerability, and pharmacokinetics study of single and multiple subcutaneous doses of turoctocog alfa pegol in patients with haemophilia A	20/04/2017	Yes	17/01/2017	02/03/2017	19/12/2016	03/03/2017	06/03/2017	06/03/2017												
72	16/WM/0514	213012	Accuracy of Detection using ENdocuff Optimisation of Mucosal Abnormalities: The B-ADENOMA Study	31/08/2017	Yes	17/01/2017	28/06/2017	20/01/2017	28/06/2017	28/06/2017	28/06/2017												
73	16/NE/0418	211187	A phase III multicentre randomised controlled trial to compare the efficacy of Robotically Assisted Radical Cystectomy (RARC) and intracorporeal urinary diversion with Open Radical Cystectomy (ORC) in patients with bladder cancer	06/06/2017	Yes	08/02/2017	10/05/2017	25/01/2017	10/05/2017	10/05/2017	12/05/2017												
74	16/WM/0391	193794	The reality of myoelectric prostheses: Understanding the impact of skill, uncertainties and delays on the control of myoelectric prostheses	07/06/2017	Yes	24/01/2017	30/03/2017	15/12/2016	03/04/2017	03/04/2017	27/04/2017												
75	17/YH/0163	223768	Improving glucose control in patients with diabetes following myocardial infarction: The role of a novel glycaemic monitoring strategy	12/09/2017	Yes	05/05/2017	31/08/2017	04/07/2017	17/07/2017	01/09/2017	05/09/2017												

76	17/NW/0471	231203	An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation	08/11/2017	Yes	03/08/2017	29/09/2017	20/09/2017	29/09/2017	03/10/2017	12/10/2017												
77	17/SC/0164	210735	A multi-centre, randomised, controlled trial evaluating the effects of early high-dose cryoprecipitate in adult patients with major trauma haemorrhage requiring major haemorrhage protocol (MHP) activation. CRYOSTAT-2 - Early cryoprecipitate in trauma	27/10/2017	Yes	30/03/2017	03/10/2017	26/05/2017	04/10/2017	05/10/2017	10/10/2017												
78	17/EM/0014	219556	Prospective Clinical Investigation for a Randomized, Controlled, Multicenter Non-inferiority Study Comparing Standard Wound Closure Technique with Drains (control) to Standard Wound Closure Techniques with TissuGlu® and No Drains (test) in Mastectomy.	02/08/2017	Yes	13/04/2017	20/06/2017	10/03/2017	20/06/2017	23/06/2017	23/06/2017												
79	17/NW/0374	226708	A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors	16/10/2017	Yes	12/06/2017	05/09/2017	18/07/2017	29/08/2017	05/09/2017	04/10/2017												
80	17/WM/0239	223251	Ankle Injury Rehabilitation - A multi-centre randomised controlled trial into rehabilitation for ankle fractures	01/12/2017	Yes	01/09/2017	20/11/2017	04/07/2017	20/11/2017	30/11/2017	30/11/2017												
81	17/YH/0359	233992	Does bowel preparation (either as a single or divided dose) produce better cleansing and diagnostic yield than no preparation at all in small bowel capsule endoscopy	04/12/2017	Yes	14/09/2017	23/11/2017	23/11/2017	23/11/2017	23/11/2017	23/11/2017												